Current Weather

Right Now
  • Humidity: 26%
  • Cloud Coverage:%
  • Wind: 11 mph
  • UV Index: 5 Moderate
  • Sunrise: 06:37:19 AM
  • Sunset: 06:50:43 PM


Lots of sunshine. High 73F. Winds ESE at 10 to 15 mph.


Clear skies. Low 43F. Winds ESE at 5 to 10 mph.


Sunny. High 76F. Winds SSE at 5 to 10 mph.

Recent Obituaries

Local & Social Scene

Follow us on Facebook

Special Sections Spotlight

  • Updated

INDIANAPOLIS, Sept. 20, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Verzenio(®) (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) significantly decreased the risk of breast cancer recurrence by 25 percent compared to standard adjuvant ET alone for people with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer (HR: 0.747; 95% CI: 0.598, 0.932; p = 0.0096). This statistically significant benefit was consistent across all pre-specified subgroups and corresponds to a 3.5 percent difference between arms (92.2 percent in the Verzenio arm and 88.7 percent in the control arm) at two years. These results are from a preplanned interim analysis with 323 IDFS events observed in the intent-to-treat population across both arms, including 136 in the Verzenio arm and 187 in the control arm. The data were presented today in the Presidential Symposium at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress and simultaneously published in the Journal of Clinical Oncology.